Patents by Inventor Henry A. Havel

Henry A. Havel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220184051
    Abstract: Formulations of tegavivint and related compounds, methods of making such formulations and methods of treating various conditions utilizing such formulations.
    Type: Application
    Filed: February 25, 2022
    Publication date: June 16, 2022
    Inventors: Steven David Dykstra, Henry Havel, Stephen Horrigan, Roger Harrison, Jeffrey Larson, Jonathan Northrup, Theodore Laslo, Garry Gwozdz
  • Patent number: 11266637
    Abstract: Formulations of tegavivint and related compounds, methods of making such formulations and methods of treating various conditions utilizing such formulations.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: March 8, 2022
    Inventors: Steven David Dykstra, Henry Havel, Stephen Horrigan, Roger Harrison, Jeffrey Larson, Jonathan Northrup, Theodore Laslo, Garry Gwozdz
  • Publication number: 20190365729
    Abstract: Formulations of tegavivint and related compounds, methods of making such formulations and methods of treating various conditions utilizing such formulations.
    Type: Application
    Filed: May 31, 2019
    Publication date: December 5, 2019
    Inventors: Steven David Dykstra, Henry Havel, Stephen Horrigan, Roger Harrison, Jeffrey Larson, Jonathan Northrup, Theodore Laslo, Garry Gwozdz
  • Patent number: 7550434
    Abstract: A stabilized pharmaceutical composition in the form of a solution for parenteral administration of a parathyroid hormone is described wherein the therapeutically active ingredient is stabilized with a buffer and a polyol. Preferred preparations contain in an aqueous solution human PTH(1-34), mannitol, an acetate or tartrate buffering agent and m-cresol or benzyl alcohol as a preservative.
    Type: Grant
    Filed: October 2, 2006
    Date of Patent: June 23, 2009
    Assignee: Eli Lilly and Company
    Inventors: Chin-Ming Chang, Henry A. Havel
  • Publication number: 20070021344
    Abstract: A stabilized pharmaceutical composition in the form of a solution for parenteral administration of a parathyroid hormone is described wherein the therapeutically active ingredient is stabilized with a buffer and a polyol. Preferred preparations contain in an aqueous solution human PTH (1-34), mannitol, an acetate or tartrate buffering agent and m-cresol or benzyl alcohol as a preservative.
    Type: Application
    Filed: October 2, 2006
    Publication date: January 25, 2007
    Inventors: Chin-Ming Chang, Henry Havel
  • Publication number: 20070021343
    Abstract: A stabilized pharmaceutical composition in the form of a solution for parenteral administration of a parathyroid hormone is described wherein the therapeutically active ingredient is stabilized with a buffer and a polyol. Preferred preparations contain in an aqueous solution human PTH(1-34), mannitol, an acetate or tartrate buffering agent and m-cresol or benzyl alcohol as a preservative.
    Type: Application
    Filed: October 2, 2006
    Publication date: January 25, 2007
    Inventors: Chin-Ming Chang, Henry Havel
  • Patent number: 7144861
    Abstract: A stabilized pharmaceutical composition in the form of a solution for parenteral administration of a parathyroid hormone is described wherein the therapeutically active ingredient is stabilized with a buffer and a polyol. Preferred preparations contain in an aqueous solution human PTH(1–34), mannitol, an acetate or tartrate buffering agent and m-cresol or benzyl alcohol as a preservative.
    Type: Grant
    Filed: January 23, 2002
    Date of Patent: December 5, 2006
    Assignee: Eli Lilly and Company
    Inventors: Chin-Ming Chang, Henry A. Havel
  • Publication number: 20050043228
    Abstract: The present invention encompasses compositions wherein a GLP-1 compound is complexed with a basic polypeptide. The compositions provide a prolonged duration of action and can be administered by the pulmonary route.
    Type: Application
    Filed: May 21, 2002
    Publication date: February 24, 2005
    Inventors: Michael DeFelippis, Henry Havel, Kenneth Mace, Kingman Ng, Virender Sarin
  • Patent number: 6770623
    Abstract: A stabilized pharmaceutical composition in the form of a solution for parenteral administration of a parathyroid hormone is described wherein the therapeutically active ingredient is stabilized with a buffer and a polyol. Preferred preparations contain in an aqueous solution human PTH(1-34), mannitol, an acetate or tartrate buffering agent and m-cresol or benzyl alcohol as a preservative.
    Type: Grant
    Filed: May 31, 2000
    Date of Patent: August 3, 2004
    Assignee: Eli Lilly and Company
    Inventors: Chin-Ming Chang, Henry A. Havel
  • Publication number: 20030225000
    Abstract: A stabilized pharmaceutical composition in the form of a solution for parenteral administration of a parathyroid hormone is described wherein the therapeutically active ingredient is stabilized with a buffer and a polyol. Preferred preparations contain in an aqueous solution human PTH(1-34), mannitol, an acetate or tartrate buffering agent and m-cresol or benzyl alcohol as a preservative.
    Type: Application
    Filed: April 30, 2003
    Publication date: December 4, 2003
    Inventors: Chin-Ming Chang, Henry A. Havel
  • Publication number: 20020107200
    Abstract: A stabilized pharmaceutical composition in the form of a solution for parenteral administration of a parathyroid hormone is described wherein the therapeutically active ingredient is stabilized with a buffer and a polyol. Preferred preparations contain in an aqueous solution human PTH(1-34), mannitol, an acetate or tartrate buffering agent and m-cresol or benzyl alcohol as a preservative.
    Type: Application
    Filed: January 23, 2002
    Publication date: August 8, 2002
    Inventors: Chin-Ming Chang, Henry A. Havel
  • Patent number: 5663305
    Abstract: The present invention provides analogs of animal somatotropins particularly with changes in the amino acids between residue 96 to 133 which are changed to reduce hydrophobicity or helical stability.
    Type: Grant
    Filed: December 29, 1994
    Date of Patent: September 2, 1997
    Assignee: The Upjohn Company
    Inventors: Sherwood Russ Lehrman, Henry A. Havel, Jody L. Tuls, Scott M. Plaisted, David N. Brems
  • Patent number: 5547929
    Abstract: The present invention discloses various parenteral pharmaceutical formulations, which comprise a mixture of a monomeric insulin analog and insulin-NPH. The analog formulations provide a rapid onset and a prolonged duration of action.
    Type: Grant
    Filed: September 12, 1994
    Date of Patent: August 20, 1996
    Assignee: Eli Lilly and Company
    Inventors: James H. Anderson, Jr., Michael R. De Felippis, Bruce H. Frank, Henry A. Havel
  • Patent number: 5474978
    Abstract: The present invention discloses a human insulin analog hexamer complex and formulations. More specifically, the present invention relates to various parenteral formulations, which comprise: human insulin analogs in a hexamer conformation, zinc ions, and at least three molecules of a phenolic derivative selected from the group consisting of m-cresol, phenol, or a mixture of m-cresol and phenol. The formulation provides a rapid onset of action.
    Type: Grant
    Filed: June 16, 1994
    Date of Patent: December 12, 1995
    Assignee: Eli Lilly and Company
    Inventors: Diane L. Bakaysa, David N. Brems, Bruce H. Frank, Henry A. Havel, Allen H. Pekar